Precision medicine research at Karmanos comparing biomarker
4.5 (449) · $ 30.00 · In stock
A Barbara Ann Karmanos Cancer Institute clinical researcher and her team have received $16,000 to further research in precision medicine for breast cancer treatment. Common Citizen leadership delivered the check to Jailan Elayoubi, M.D. , medical oncologist and member of the Breast Cancer and Phase 1 Clinical Trials Multidisciplinary Teams, in November 2023. Dr. Elayoubi and her team have made significant strides in studying biomarkers and tumor molecular characteristics that may predict sensitivity and
Halabi et al KCJ19n3 2021
The Evolution of Biomarker Use in Clinical Trials for Cancer
Karmanos Cancer Institute
IN THE NEWS: Karmanos Cancer Institute Expands into Ohio
Blood-based tumor biomarkers in lung cancer for detection and
Biomarker development in the precision medicine era: lung cancer
Barbara Ann Karmanos Cancer Institute
Biomarker-Driven Clinical Trials
JCM, Free Full-Text
Current Institutions Participating in the PROMISE Consortium
PDF) TMB: a promising immune-response biomarker, and potential
